Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Chinese journal of integrative medicine ; (12): 272-277, 2018.
Article in English | WPRIM | ID: wpr-691376

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the effect of combined application of Xuebijing Injection ( , XBJ) and resolvin D1 (RvD1) on survival rate and the underlying mechanisms in mice with sepsisinduced lung injury.</p><p><b>METHODS</b>The cecal ligation and puncture (CLP) method was used to develop a mouse sepsis model. Specific pathogen free male C57BL/6 mice were randomly divided into 5 groups (n=20 each): sham, CLP, CLP+XBJ, CLP+RvD1 and CLP+XBJ+RvD1. After surgery, mice in the CLP+XBJ, CLP+RvD1 and CLP+XBJ+RvD1 groups were given XBJ (25 μL/g body weight), RvD1 (10 ng/g body weight), and their combination (the same dose of XBJ and RvD1), respectively. In each group, 12 mice were used to observe 1-week survival rate, while the rest were executed at 12 h. Whole blood was collected for flow cytometric analysis of leukocyte adhesion molecules CD18, lung tissues were harvested for observing pathological changes, and testing the activity of myeloperoxidase (MPO) and the expression of intercellular cell adhesion molecule 1 (ICAM-1).</p><p><b>RESULTS</b>Compared with the CLP group, the histopathological damage of the lung tissues was mitigated, MPO activity was decreased in the CLP+XBJ and CLP+RvD1 groups (P<0.05). In addition, the 1-week survival rate was improved, proportion of CD18-expressing cells in whole blood and ICAM-1 protein expression in lung tissue were decreased in the CLP+XBJ+RvD1 group (P<0.05 or P<0.01).</p><p><b>CONCLUSIONS</b>XBJ together with RvD1 could effectively inhibit leukocyte adhesion, reduce lung injury, and improve the survival rate of mice with sepsis.</p>


Subject(s)
Animals , Male , CD18 Antigens , Metabolism , Cell Adhesion , Docosahexaenoic Acids , Pharmacology , Therapeutic Uses , Drugs, Chinese Herbal , Pharmacology , Therapeutic Uses , Injections , Intercellular Adhesion Molecule-1 , Metabolism , Leukocytes , Metabolism , Pathology , Lung , Pathology , Lung Injury , Blood , Drug Therapy , Mice, Inbred C57BL , Peroxidase , Metabolism , Sepsis , Blood , Drug Therapy , Survival Analysis
2.
Journal of Huazhong University of Science and Technology (Medical Sciences) ; (6): 529-533, 2016.
Article in English | WPRIM | ID: wpr-285234

ABSTRACT

Intraportal transplantation of islets is no longer considered to be an ideal procedure and finding the extrahepatic alternative site is becoming a subject of high priority. Herein, in this study, we would introduce our initial outcomes of using gastric submucosa (GS) and liver as sites of islet autotransplantation in pancreatectomized diabetic Beagles. Total pancreatectomy was performed in Beagles and then their own islets extracted from the excised pancreas were transplanted into GS (GS group, n=8) or intrahepatic via portal vein (PV group, n=5). Forty-eight hours post transplantation, graft containing tissue harvested from the recipients revealed the presence of insulin-positive cells. All recipients in GS group achieved euglycemia within 1 day, but returned to a diabetic state at 6 to 8 days post-transplantation (mean survival time, 7.16±0.69 days). However, all of the animals kept normoglycemic until 85 to 155 days post-transplantation in PV group (mean survival time, 120±28.58 days; P<0.01 vs. GS group). The results of intravenous glucose tolerance test (IVGTT) confirmed that the marked improvement in glycometabolism was obtained in intrahepatic islet autotransplantation. Thus, our findings indicate that the liver is still superior to the GS as the site of islet transplantation, at least in our islet autotransplant model in pancreatectomized diabetic Beagles.


Subject(s)
Animals , Dogs , Humans , Diabetes Mellitus, Experimental , Metabolism , Pathology , Therapeutics , Gastric Mucosa , Metabolism , Transplantation , Glucose , Metabolism , Glucose Tolerance Test , Graft Survival , Insulin , Metabolism , Islets of Langerhans Transplantation , Liver , Pathology , Liver Transplantation , Transplantation, Autologous
3.
The Korean Journal of Physiology and Pharmacology ; : 1-7, 2015.
Article in English | WPRIM | ID: wpr-727833

ABSTRACT

Our previous study has shown berberine prevents damage to the intestinal mucosal barrier during early phase of sepsis in rat through mechanisms independent of the NOD-like receptors signaling pathway. In this study, we explored the regulatory effects of berberine on Toll-like receptors during the intestinal mucosal damaging process in rats. Male Sprague-Dawlay (SD) rats were treated with berberine for 5 d before undergoing cecal ligation and puncture (CLP) to induce polymicrobial sepsis. The expression of Toll-like receptor 2 (TLR 2), TLR 4, TLR 9, the activity of nuclear factor-kappa B (NF-kappaB), the levels of selected cytokines and chemokines, percentage of cell death in intestinal epithelial cells, and mucosal permeability were investigated at 0, 2, 6, 12 and 24 h after CLP. Results showed that the tumor necrosis factor-alpha (TNF-alpha ) and interleukin-6 (IL-6) level were significantly lower in berberine-treated rats compared to the control animals. Conversely, the expression level of tight junction proteins, percentage of cell death in intestinal epithelial cells and the mucosal permeability were significantly higher in berberine-treated rats. The mRNA expression of TLR 2, TLR 4, and TLR 9 were significantly affected by berberine treatment. Our results indicate that pretreatment with berberine attenuates tissue injury and protects the intestinal mucosal barrier in early phase of sepsis and this may possibly have been mediated through the TLRs pathway.


Subject(s)
Animals , Humans , Male , Rats , Berberine , Cell Death , Chemokines , Cytokines , Epithelial Cells , Interleukin-6 , Intraabdominal Infections , Ligation , Permeability , Punctures , RNA, Messenger , Sepsis , Tight Junction Proteins , Toll-Like Receptor 2 , Toll-Like Receptors , Tumor Necrosis Factor-alpha
4.
Chinese Journal of Gastrointestinal Surgery ; (12): 859-861, 2012.
Article in Chinese | WPRIM | ID: wpr-321516

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the relationship between the type 1 diabetic rats residual islet function and postoperative glycemia of gastric bypass procedure (GBP).</p><p><b>METHODS</b>Intraperitoneal injection of STZ was used to produce type 1 diabetic rat model. According to the level of serum glucose, rats were divided into two groups: group 1 (fasting glucose 16.7-22.0 mmol/L, n=42) and group 2 (fasting glucose>22.0 mmol/L, n=54). Half rats of group 1 and group 2 received GBP, which were OP1 group (n=21) and OP2 group (n=27). The normal control group included 20 Wistar rats. The fasting glycemia and fasting C-peptide (C-P) were tested at postoperative weeks 1, 2, 3, and pancreas pathological slices were examined 3 weeks after surgery under microscope.</p><p><b>RESULTS</b>After GBP, the C-P was elevated and the glycemia was well controlled in OP1 group compared with group 1 (P<0.05). But the C-P was not significantly increased and the glycemia control was poor compared with group 2 (P>0.05). Pathological examination revealed that there were partial islets residual in pancrease of group 1, the islets were shown obvious hyperplasia in OP1 group after GBP. There were almost no islets residual in pancrease of group 2, and the islets were shown no obvious hyperplasia in OP2 group after GBP.</p><p><b>CONCLUSIONS</b>Residual islet function determines the glycemia changes of type 1 diabetic rats after gastric bypass.</p>


Subject(s)
Animals , Female , Male , Rats , Blood Glucose , Metabolism , Diabetes Mellitus, Experimental , Metabolism , General Surgery , Gastric Bypass , Pancreas , Postoperative Period , Rats, Wistar
5.
Chinese Journal of Surgery ; (12): 1068-1071, 2012.
Article in Chinese | WPRIM | ID: wpr-247915

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the early diagnosis and treatment of acute mesenteric ischemia.</p><p><b>METHODS</b>Forty-two patients with acute mesenteric ischemia from June 2007 to November 2011 were reviewed retrospectively. All patients were diagnosed with DSA and (or) CT and (or) surgery. In this group, there were 32 cases of acute occlusion of meseteric ischemia (AOMI), 9 cases of superior mesenteric venous thrombosis (SMVT) and 1 case of non-occlusive mesenteric ischemia. The patients were treated using comprehensive treatment including early intervention treatment and application of the principle of damage control. The survival of all patients was followed up for 6 months or more in outpatient.</p><p><b>RESULTS</b>(1) Of the 32 AOMI cases, 4 cases healing by systemic anticoagulation; The 19 cases received interventional treatment, including 10 cases received simply interventional treatment, surgery after the failure of intervention in 5 cases, 3 patients died without surgery and postoperative interventional treatment one cases were cured; Eight cases received surgery treatment; One case gave up. (2) Of the 9 SMVT cases, 2 cases healing by systemic anticoagulation; The 6 cases received interventional treatment, including 1 cases received simply interventional treatment, surgery after the failure of intervention in 1 cases, 4 cases to consider intestinal necrosis received interventional treatment again after surgery; One patient died without treatment. (3) Eight cases received delay abdomen close treatment with the principle of damage control surgery. The overall mortality rate of 23.8% (10/42). Interventional treatment of 26 cases, 4 deaths, a mortality rate of 15.3%; The abdomen delayed close of 8 cases, 1 death.</p><p><b>CONCLUSIONS</b>The results show that early diagnosis and treatment is critical to reduce AMI mortality. Comprehensive treatment of early intervention treatment and application of the principle of damage control can significantly reduce the mortality of AMI.</p>


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Young Adult , Early Diagnosis , Ischemia , Diagnosis , Therapeutics , Mesenteric Ischemia , Retrospective Studies , Tomography, X-Ray Computed , Vascular Diseases , Diagnosis , Therapeutics
SELECTION OF CITATIONS
SEARCH DETAIL